Objective: To analyze the various factors affecting the economic burden of disease in patients with epilepsy.
Methods: This research used a multi-stage random sampling method, comprehensive intervention and without intervention of the epilepsy project group conducted a field survey of health examination among patients with epilepsy of 874 (422 cases in intervention group and 452 cases in control group) in Mengzhou, Xiuwu, Yancheng, Yuanhui, Wuyang, Linying, Shaoling, Xinye and Fangcheng. DALY indicators combined with human capital approach was used to measure the economic burden of disease in patients from two aspects of the direct economic burden and indirect economic burden.
Results: The age of comprehensive intervention group was (43.7 ± 8.5) years old, and it was (44.4 ± 7.2) years old in no intervention control group. The age difference was not statistically significant (P = 0.365). The direct economic burden per capita of the survey was 1019.6 yuan per year, while epilepsy drugs 434.2 yuan per year, 485.2 and 66.4 yuan per year in the intervention group, while 1518.5 and 777.5 yuan per year in the control group. Each object in this study lost (16.67 ± 10.01) DALY, with 8.58 DALY in intervention group and 24.23 DALY in no intervention control group. The per capita indirect economic burden of the intervention and control groups were 68 115.2, 401 036.5 yuan, the per capita total economic burden of disease were 68 600.5, 408 755.0 yuan. Multivariate logistic regression analysis showed that disease duration year of ≥ 37, 30 - 36, 20 - 29, 10 - 19, OR (95%CI) were 4.44 (2.37 - 8.33), 3.32 (1.85 - 5.94), 3.25 (1.90 - 5.56), 2.53 (1.46 - 4.41). If patients with longer duration, the more serious the patient's disease burden. Medication compliance (in order to comply with a good group control) OR (95%CI) was 3.37 (2.34 - 4.83), medication in the single form (serving multi-drug groups for control) OR (95%CI) 0.41 (0.29 - 0.59). Serving a single agent and good compliance of economic burden of disease were lighter.
Conclusion: Epilepsy caused serious economic damage. Longer duration, medication adherence poor and serving more than medicine by heavier economic burden of disease; comprehensive intervention could reduce the economic burden of disease of patients with epilepsy.